After yesterday's alzheimer-cochrane-critique-hardens-day-eight-with-no-policy-reset, Day Nine adds no public shift from FDA or CMS. At this duration, non-response is no longer a neutral waiting period. It is an operating posture.

Cochrane's claim remains clear: across the reviewed anti-amyloid trial set, average clinical effect was absent or trivial against meaningful-change thresholds, with safety tradeoffs still present [1]. U.S. reimbursement and labeling pathways, however, remain unchanged in public-facing channels. That disconnect is now the live policy signal.

In practical terms, clinicians and families continue inside the pre-critique system unless regulators say otherwise. The paper's frame therefore hardens one more day: evidence has moved, institutions have not, and silence now allocates the burden of uncertainty back to bedside decisions rather than agency-level rulemaking [2][3].

The calendar effect is now part of the claim. Each additional day without explicit regulator language increases the odds that payers, providers, and patients treat the status quo as settled through inertia alone. Day Nine is therefore not repetitive coverage; it is the measure of policy by omission [1][3].

-- NORA WHITFIELD, Chicago